$1.18
0.84% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US92854B1098
Symbol
VANI
Sector

Vivani Medical Stock price

$1.18
-0.27 18.62% 1M
-0.09 7.09% 6M
+0.16 15.69% YTD
+0.14 13.46% 1Y
-4.34 78.62% 3Y
-16.58 93.36% 5Y
-253.70 99.54% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.01 0.84%
ISIN
US92854B1098
Symbol
VANI
Sector

Key metrics

Market capitalization $69.90m
Enterprise Value $70.31m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.56
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-24.43m
Free Cash Flow (TTM) Free Cash Flow $-19.46m
Cash position $19.65m
EPS (TTM) EPS $-0.44
P/E forward negative
Short interest 2.50%
Show more

Is Vivani Medical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Vivani Medical Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Vivani Medical forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Vivani Medical forecast:

Buy
100%

Financial data from Vivani Medical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.41 0.41
11% 11%
-
-0.41 -0.41
11% 11%
-
- Selling and Administrative Expenses 7.47 7.47
33% 33%
-
- Research and Development Expense 16 16
3% 3%
-
-24 -24
15% 15%
-
- Depreciation and Amortization 0.41 0.41
11% 11%
-
EBIT (Operating Income) EBIT -24 -24
14% 14%
-
Net Profit -23 -23
13% 13%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vivani Medical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vivani Medical Stock News

Neutral
Business Wire
10 days ago
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing novel, ultra long-acting drug implants, today announced that screening and enrollment of the first-in-human clinical trial, known as LIBERATE-1™, has been initiated at two centers in Australia to investigate the safety, tolerability and full pharm...
Neutral
Business Wire
25 days ago
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the Innovation in Obesity Therapeutics Summit West Coast, taking place in San Diego, California, ...
Neutral
Business Wire
about 2 months ago
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-acting drug implants, today reported financial results for the third quarter ended September 30, 2024, and provided a business update. Vivani's Chief Executive Officer Adam Mendelsohn, Ph.D., stated, “We made significant progress advancing ...
More Vivani Medical News

Company Profile

Vivani Medical, Inc. develops and commercializes drug and device implants that treat patients with chronic diseases with high unmet medical need. The company was founded on May 22,2003 and is headquartered in Alameda, CA.

Head office United States
CEO Adam Mendelsohn
Employees 44
Founded 2003
Website www.vivani.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today